Cargando…

Clinical and neuroimaging correlates of antiphospholipid antibodies in multiple sclerosis: a preliminary study

BACKGROUND: The presence of antiphospholipid antibodies (APLA) in multiple sclerosis (MS) patients has been reported frequently but no clear relationship between APLA and the clinical and neuroimaging features of MS have heretofore been shown. We assessed the clinical and neuroimaging features of MS...

Descripción completa

Detalles Bibliográficos
Autores principales: Bidot, Carlos J, Horstman, Lawrence L, Jy, Wenche, Jimenez, Joaquin J, Bidot, Carlos, Ahn, Yeon S, Alexander, J Steven, Gonzalez-Toledo, Eduardo, Kelley, Roger E, Minagar, Alireza
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2219992/
https://www.ncbi.nlm.nih.gov/pubmed/17945023
http://dx.doi.org/10.1186/1471-2377-7-36
_version_ 1782149322462199808
author Bidot, Carlos J
Horstman, Lawrence L
Jy, Wenche
Jimenez, Joaquin J
Bidot, Carlos
Ahn, Yeon S
Alexander, J Steven
Gonzalez-Toledo, Eduardo
Kelley, Roger E
Minagar, Alireza
author_facet Bidot, Carlos J
Horstman, Lawrence L
Jy, Wenche
Jimenez, Joaquin J
Bidot, Carlos
Ahn, Yeon S
Alexander, J Steven
Gonzalez-Toledo, Eduardo
Kelley, Roger E
Minagar, Alireza
author_sort Bidot, Carlos J
collection PubMed
description BACKGROUND: The presence of antiphospholipid antibodies (APLA) in multiple sclerosis (MS) patients has been reported frequently but no clear relationship between APLA and the clinical and neuroimaging features of MS have heretofore been shown. We assessed the clinical and neuroimaging features of MS patients with plasma APLA. METHODS: A consecutive cohort of 24 subjects with relapsing-remitting (RR) MS were studied of whom 7 were in remission (Rem) and 17 in exacerbation (Exc). All subjects were examined and underwent MRI of brain. Patients' plasma was tested by standard ELISA for the presence of both IgM and IgG antibodies using a panel of 6 targets: cardiolipin (CL), β2 glycoprotein I (β2GPI), Factor VII/VIIa (FVIIa), phosphatidylcholine (PC), phosphatidylserine (PS) and phosphatidylethanolamine (PE). RESULTS: In exacerbation up to 80% of MS subjects had elevated titers of IgM antibodies directed against the above antigens. However, in remission, less than half of MS patients had elevated titers of IgM antibodies against one or more of the above antigens. This difference was significant, p < 0.01, for all 6 target antigens. Interestingly, none of the MS patients had elevated plasma titers of IgG against any of the target antigens tested. Correlation analysis between MRI enhancing lesions and plasma levels of APLA revealed high correlation for aPC, aPS and aFVIIa (p ≤ 0.0065), a trend for aPE and aCL (p = 0.056), and no correlation for aβ2GP1. The strongest correlation was for aFVIIa, p = 0.0002. CONCLUSION: The findings of this preliminary study show that increased APLA IgM is associated with exacerbations of MS. Currently, the significance of this association in pathogenesis of MS remains unknown. However, systematic longitudinal studies to measure APLA in larger cohorts of patients with relapsing-remitting MS, particularly before and after treatment with immunomodulatory agents, are needed to confirm these preliminary findings.
format Text
id pubmed-2219992
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-22199922008-01-31 Clinical and neuroimaging correlates of antiphospholipid antibodies in multiple sclerosis: a preliminary study Bidot, Carlos J Horstman, Lawrence L Jy, Wenche Jimenez, Joaquin J Bidot, Carlos Ahn, Yeon S Alexander, J Steven Gonzalez-Toledo, Eduardo Kelley, Roger E Minagar, Alireza BMC Neurol Research Article BACKGROUND: The presence of antiphospholipid antibodies (APLA) in multiple sclerosis (MS) patients has been reported frequently but no clear relationship between APLA and the clinical and neuroimaging features of MS have heretofore been shown. We assessed the clinical and neuroimaging features of MS patients with plasma APLA. METHODS: A consecutive cohort of 24 subjects with relapsing-remitting (RR) MS were studied of whom 7 were in remission (Rem) and 17 in exacerbation (Exc). All subjects were examined and underwent MRI of brain. Patients' plasma was tested by standard ELISA for the presence of both IgM and IgG antibodies using a panel of 6 targets: cardiolipin (CL), β2 glycoprotein I (β2GPI), Factor VII/VIIa (FVIIa), phosphatidylcholine (PC), phosphatidylserine (PS) and phosphatidylethanolamine (PE). RESULTS: In exacerbation up to 80% of MS subjects had elevated titers of IgM antibodies directed against the above antigens. However, in remission, less than half of MS patients had elevated titers of IgM antibodies against one or more of the above antigens. This difference was significant, p < 0.01, for all 6 target antigens. Interestingly, none of the MS patients had elevated plasma titers of IgG against any of the target antigens tested. Correlation analysis between MRI enhancing lesions and plasma levels of APLA revealed high correlation for aPC, aPS and aFVIIa (p ≤ 0.0065), a trend for aPE and aCL (p = 0.056), and no correlation for aβ2GP1. The strongest correlation was for aFVIIa, p = 0.0002. CONCLUSION: The findings of this preliminary study show that increased APLA IgM is associated with exacerbations of MS. Currently, the significance of this association in pathogenesis of MS remains unknown. However, systematic longitudinal studies to measure APLA in larger cohorts of patients with relapsing-remitting MS, particularly before and after treatment with immunomodulatory agents, are needed to confirm these preliminary findings. BioMed Central 2007-10-18 /pmc/articles/PMC2219992/ /pubmed/17945023 http://dx.doi.org/10.1186/1471-2377-7-36 Text en Copyright © 2007 Bidot et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Bidot, Carlos J
Horstman, Lawrence L
Jy, Wenche
Jimenez, Joaquin J
Bidot, Carlos
Ahn, Yeon S
Alexander, J Steven
Gonzalez-Toledo, Eduardo
Kelley, Roger E
Minagar, Alireza
Clinical and neuroimaging correlates of antiphospholipid antibodies in multiple sclerosis: a preliminary study
title Clinical and neuroimaging correlates of antiphospholipid antibodies in multiple sclerosis: a preliminary study
title_full Clinical and neuroimaging correlates of antiphospholipid antibodies in multiple sclerosis: a preliminary study
title_fullStr Clinical and neuroimaging correlates of antiphospholipid antibodies in multiple sclerosis: a preliminary study
title_full_unstemmed Clinical and neuroimaging correlates of antiphospholipid antibodies in multiple sclerosis: a preliminary study
title_short Clinical and neuroimaging correlates of antiphospholipid antibodies in multiple sclerosis: a preliminary study
title_sort clinical and neuroimaging correlates of antiphospholipid antibodies in multiple sclerosis: a preliminary study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2219992/
https://www.ncbi.nlm.nih.gov/pubmed/17945023
http://dx.doi.org/10.1186/1471-2377-7-36
work_keys_str_mv AT bidotcarlosj clinicalandneuroimagingcorrelatesofantiphospholipidantibodiesinmultiplesclerosisapreliminarystudy
AT horstmanlawrencel clinicalandneuroimagingcorrelatesofantiphospholipidantibodiesinmultiplesclerosisapreliminarystudy
AT jywenche clinicalandneuroimagingcorrelatesofantiphospholipidantibodiesinmultiplesclerosisapreliminarystudy
AT jimenezjoaquinj clinicalandneuroimagingcorrelatesofantiphospholipidantibodiesinmultiplesclerosisapreliminarystudy
AT bidotcarlos clinicalandneuroimagingcorrelatesofantiphospholipidantibodiesinmultiplesclerosisapreliminarystudy
AT ahnyeons clinicalandneuroimagingcorrelatesofantiphospholipidantibodiesinmultiplesclerosisapreliminarystudy
AT alexanderjsteven clinicalandneuroimagingcorrelatesofantiphospholipidantibodiesinmultiplesclerosisapreliminarystudy
AT gonzaleztoledoeduardo clinicalandneuroimagingcorrelatesofantiphospholipidantibodiesinmultiplesclerosisapreliminarystudy
AT kelleyrogere clinicalandneuroimagingcorrelatesofantiphospholipidantibodiesinmultiplesclerosisapreliminarystudy
AT minagaralireza clinicalandneuroimagingcorrelatesofantiphospholipidantibodiesinmultiplesclerosisapreliminarystudy